Tianming Pharmaceutical Group Orforglipron intermediates help the new era of GLP-1 Oral small molecule GLP-1 has taken the world by storm, who is behind this revolution?
Lilly Orforglipron’s stunning data has already pointed out the direction for the industry: the oral small molecule GLP-1 drug, which requires no cold chain, no injection, and has a high degree of patient compliance, is reshaping the 100-billion-dollar market for weight loss and chronic disease management in a disruptive manner.
In this revolution, Tianming has become an important partner for global pharmaceutical companies to attack the small molecule GLP-1 track by virtue of its large-scale and high-purity production capacity of oglitazone intermediates!
As a key intermediate for the next generation of oral small molecule GLP-1 drugs, the synthesis process of omadacycline has a direct impact on the cost of the drug and clinical effects. Shandong Tianming Pharmaceutical Technology Co., Ltd. has successfully completed the process laboratory to production scale-up research of key intermediates of oral GLP-1 receptor agonist Orforglipron (LY3502970) series.
This achievement marks that TMC has mastered the whole industry chain technology and production capacity of Orforglipron intermediates, providing Chinese solutions for the global weight loss drug industry chain.
01 Policy dividend outbreak
China’s “14th Five-Year Plan” for the development of the pharmaceutical industry clearly supports the innovation of GLP-1 and other metabolic disease drugs, and accelerated review and approval of domestic breakthroughs to press the fast-forward button.
02 Market Demand Spurt
Over 600 million obese patients and 500 million diabetic patients around the world are in urgent need of better therapies. Oral small molecule GLP-1 will activate a hundred billion incremental market by virtue of the convenience of “pills instead of needles”.
In this era full of opportunities and challenges, Tianming invites partners from all walks of life to join hands and explore the unlimited possibilities of small molecule GLP-1. Let’s take professionalism as our wings and innovation as our sails, and sail together to the future blue sea of pharmaceutical science and technology.
Choosing Tianming is choosing a trustworthy partner, a pioneer who can lead the trend of the industry. Tianming, together with you, will lead the era of small molecule GLP-1 and create a new splendor of medicine!
A manufacturer’s inside look at where minimum order quantities come from, what’s reasonable at each development stage, and 5 practical strategies to get better terms.
Learn how to read a pharmaceutical intermediate COA — assay vs. purity, red flags, and a checklist that catches what suppliers leave out.
GMP sets the baseline for pharmaceutical quality. cGMP demands you keep up with the times. Here’s what the difference means for buyers sourcing APIs and intermediates.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.